Icon Plc $ICLR Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC lowered its stake in shares of Icon Plc (NASDAQ:ICLR) by 6.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 49,137 shares of the medical research company’s stock after selling 3,172 shares during the period. Corient Private Wealth LLC’s holdings in Icon were worth $8,954,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Sanctuary Advisors LLC boosted its stake in shares of Icon by 1.1% in the fourth quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock worth $899,000 after buying an additional 56 shares during the last quarter. Geneos Wealth Management Inc. grew its holdings in Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares during the period. New Wave Wealth Advisors LLC raised its position in Icon by 5.1% during the fourth quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock valued at $270,000 after acquiring an additional 72 shares in the last quarter. Signaturefd LLC raised its position in Icon by 12.6% during the fourth quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock valued at $117,000 after acquiring an additional 72 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in Icon by 0.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock valued at $4,363,000 after acquiring an additional 93 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Trading Up 10.9%

Shares of Icon stock opened at $158.17 on Thursday. The firm has a market capitalization of $12.11 billion, a PE ratio of 28.14, a P/E/G ratio of 11.70 and a beta of 1.26. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The firm’s 50-day moving average price is $127.61 and its 200 day moving average price is $138.23. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.31.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Tuesday, June 23rd. The medical research company reported $2.50 EPS for the quarter, topping the consensus estimate of $2.43 by $0.07. Icon had a return on equity of 8.71% and a net margin of 5.35%.The company had revenue of $2.03 billion during the quarter, compared to analyst estimates of $1.98 billion. During the same period in the previous year, the business earned $3.43 EPS. Icon’s quarterly revenue was up 2.5% on a year-over-year basis. On average, sell-side analysts predict that Icon Plc will post 9.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

ICLR has been the topic of several recent research reports. BMO Capital Markets upped their price objective on Icon from $130.00 to $160.00 and gave the stock an “outperform” rating in a research report on Friday, May 29th. Leerink Partners set a $145.00 target price on shares of Icon in a report on Thursday, May 28th. Zacks Research downgraded shares of Icon from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 25th. Bank of America restated an “outperform” rating on shares of Icon in a research report on Monday, June 1st. Finally, Citigroup lifted their price objective on shares of Icon from $120.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, May 29th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $153.31.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.